Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Market Insight - Influenza: the avoidable killer

This article was originally published in Scrip

Executive Summary

Despite the long-standing availability of vaccines, seasonal influenza still accounts for 300,000-500,000 deaths annually worldwide,1 and creates considerable economic strain and burden on healthcare providers, during the intense four- to five-month influenza season each year. Not only do challenges remain in the reduction of morbidity and mortality caused by seasonal influenza, a real threat of pandemic influenza is today a genuine and increasing concern. The current environment surrounding influenza is therefore one of significant investment, regulatory and policy change, and global co-operation efforts in an attempt to minimise the burden of seasonal influenza and maximise preparedness for a pandemic.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC003243

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel